1: Okyo Pharma and the roadmap to IND submission to the FDA for dry eye treatment in 2022

<div>Dr. Gary S. Jacob, Chief Executive Officer of OKYO discusses the latest from the dry eye treatment company regarding positive results of OK-201, a non-opioid analgesic drug candidate. He also runs through developments at OKYO since he became CEO earlier this year, as well as timelines to future milestones at the company.</div>